Stay updated on Nivolumab vs Docetaxel in Squamous NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in Squamous NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Docetaxel in Squamous NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The Chile site listing for Valparaiso was updated by removing the explicit “Región de Valparaíso” label and switching to a shorter format ("Viña del Mar, Valparaiso, Chile"). The page footer version/revision also changed from v3.5.2 to v3.5.3.
    Difference
    0.3%
    Check dated 2026-04-24T06:10:23.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:38:49.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Padua, Italy 35128 was replaced with Padova, Italy 35128 in the Italy locations section.
    Difference
    0.0%
    Check dated 2026-04-09T21:37:43.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T06:09:26.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-12T00:29:45.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the old government-funding status notice. These are administrative updates that do not alter the study details or user interactions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-11T14:06:41.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Docetaxel in Squamous NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in Squamous NSCLC Clinical Trial page.